Imatinib vs Pembrolizumab
Imatinib vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Imatinib and Pembrolizumab.
Mechanism of Action
Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Imatinib — 18 hours; Pembrolizumab — 26 days.
Chemical Properties
Molecular Formula: Imatinib — C29H31N7O.
Molecular Weight: Imatinib — 493.6030 g/mol.
Type: Imatinib — Small molecule; Pembrolizumab — Antibody.